Noveris Health Sciences Inc. MYCOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.11% | -78.07% | -78.86% | -67.67% | -55.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.20% | -80.41% | -81.05% | -121.11% | -95.71% |
| Operating Income | -236.20% | 80.41% | 81.05% | 121.11% | 95.71% |
| Income Before Tax | 961.23% | 161.78% | 188.43% | 117.73% | 101.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 961.23% | 161.78% | 188.43% | 117.73% | 101.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 961.23% | 161.78% | 188.43% | 117.73% | 101.27% |
| EBIT | -236.20% | 80.41% | 81.05% | 121.11% | 95.71% |
| EBITDA | -- | -- | -- | 128.04% | 105.22% |
| EPS Basic | 1,878.29% | 220.15% | 183.98% | 115.46% | 101.03% |
| Normalized Basic EPS | 59.40% | 84.21% | 78.95% | 106.62% | 92.57% |
| EPS Diluted | 1,878.29% | 220.15% | 183.98% | 115.46% | 101.03% |
| Normalized Diluted EPS | 59.40% | 84.21% | 78.95% | 106.62% | 92.57% |
| Average Basic Shares Outstanding | 1,457.15% | 297.38% | 3.62% | 9.14% | 27.79% |
| Average Diluted Shares Outstanding | 1,457.15% | 297.38% | 3.62% | 9.14% | 27.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |